The program aims to consent up to 150,000 patients to a larger biobank program and return selective preemptive PGx results through their medical center physicians.
HTG will leverage existing collaborations with firms including Illumina and Thermo Fisher Scientific tocontinue building in vitro diagnostic assays on their sequencers.
Thermo Fisher will codevelop LC-MS workflows for infectious disease detection with NanoPin and will commercialize Q-linea's antibiotic susceptibility testing platform.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
DiaSorin got the nod for the Liaison Lyme Total Antibody Plus assay which uses chemiluminescence to detect lgG and IgM antibodies to Borrelia burgdorferi.
While overall revenues and net income were up, analytical instruments revenues decreased 3 percent in Q4, and 2 percent organically.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing.
In one of two clearances, Beckman Coulter got the go-ahead to market its Access PCT chemiluminescent immunoassay for measuring levels of procalcitonin.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.